Vera expands atacicept program to broader IgAN and autoimmune kidney diseases with two new studies

Vera Therapeutics, Inc.

ORIGIN Extend to start Q4 2024, providing extended atacicept access and long-term data for ORIGIN participants.
PIONEER study in 2025 will evaluate atacicept in expanded IgAN populations (low eGFR, high/low proteinuria, recurrence post-transplant, adolescents) and podocytopathies (pMN, FSGS, MCD).
Combined US peak prevalence of IgAN and autoimmune-driven pMN, FSGS, MCD estimated at ~230,000.
96-week Phase 2b ORIGIN data to be presented as Late Breaking Oral at ASN Kidney Week 2024.
Multiple regulatory and clinical milestones expected over next 18 months.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.